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Dear Editor,
in the end of 2019, a series of pneumonia cases emerged in China, with clinical presentations 
greatly resembling viral pneumonia, caused by  Covid-19 o SARS-CoV-21.
Currently, several clinicians described an increasingly cases of coronavirus-positive patients 
reporting skin problems, either in early stage of infection or as late onset manifestation2-4.
Recently, Dr. Sebastiano Recalcati analyzed the cutaneous involvement in 148 COVID-19 patients 
hospitalized in the Lecco Hospital, Lombardy, Italy5. 
Among them, 18 patients developed cutaneous involvement with  erythematous rash, urticaria and 
chickenpox-like vesicles5. 
In light of these data, in the absence of a related histological analysis, it is not possible to 
determine whether these clinical manifestations are attributable to direct viral action or to other 
factors.
We report a patient with a history of Covid-19 infection and a late onset cutaneous eruption, after 
healing.
A 47-year-old auxiliary hospital worker, with a history of hypertension and impair glucose 
tolerance, in service at a hospital located in one of the Italian Covid-19 red zones, had a syncope 
during his work shift, so urgent CT scan was performed.
The radiological report showed, unexpectedly, pulmonary ground-glass opacifications, mainly 
involving the right lower lobe.
Consequently, nasopharyngeal and oropharyngeal swabs were performed for Covid-19 on March 
25, 2020: the tests were positive for SARS-CoV-2.
Pertinent laboratory results on admission revealed only elevated RCP (2,11 mg/dl).A
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Supportive, antibiotic, antiviral and anticoagulant (Ceftriaxon, Lopinavir/Ritonavir, 
Hidroxicloroquina, Enoxaparin) care were carried with good clinical response. 
Neither high fever nor severe respiratory symptoms were noticed.
Firstly on April 2, and once again on April 4, the control swabs were negative, therefore, given his 
health status, the patient was discharged from hospital on April 8, 2020. 
Four days later, patient reported appearance of persistent, progressive, erythematous and itchy 
lesions, with cranio-caudal displacement.
Symptoms get worse quickly, so he went to E.R. where he was given intravenous steroid and 
antihistamine agent, with mild benefit.
Blood test revealed an increased in white blood cells (22,27x10^3/ul) especially in neutrophils 
(19,52 x10^3/ul).
Dermatologic consultation revealed multiple, raised erythematous wheals, alone or in cluster, 
some of them with central purple hyperpigmentation, predominantly localized on head, trunk and 
upper arms. (Fig. 1a)
Patient complained of intense itching.
A diagnosis of suspected urticarial vasculitis has been made. 
In attempt to rule out if this clinical manifestation was linked to viral reactivation, nasopharyngeal 
and oropharyngeal swabs were executed again, resulting negative for SARS-CoV2.
The blood test for autoimmune disease was negative (ANA, ENA screening, ANCA, 
antiphospholipid, C3,C4).
Punch biopsy was performed and histological examination revealed orthokeratotic hyperkeratosis, 
spongiosis, focal vacuolar degeneration of basal keratinocytes and focal lymphocytic exocytosis. 
Slight inflammatory lymphomorphonuclear infiltrate of superficial dermis with minimal 
perivascular neutrophilic component was observed, with occasional aspects of vessel wall damage. 
(Fig. 1b)
Thus, the histopathologic diagnosis of a plausible adverse drug reaction was established.
Therefore, the patient was treated as Urticarial Vasculitis due to adverse drug reaction with 
tapering Prednisone, Bilastine and Pantoprazole with prior authorization of diabetes specialist, 
given the evidence of recent onset diabetes mellitus.
After 7 days patient presented a complete symptom remission.
Currently, cases of different COVID-19-related skin manifestations are frequently described6-7. A
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We recognize the limitations of this single case report; however further experiences are 
required to distinguish how often skin involvement is closely related to virus and how frequently 
it could be related to anti Covid-19 multidrug treatment.
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Figure 1a: clinical pictures 
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Figure 1b: histology pictures 
